Kimberly-Clark Moves to Acquire Kenvue, Forging a $32 Billion Consumer Care Powerhouse

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating one of the world's largest consumer health and household goods companies.

Deal Details

Under the agreement, Kenvue shareholders will receive $3.50 in cash and 0.14625 Kimberly-Clark shares for each Kenvue share, valuing Kenvue at $21.01 per share.

Kimberly-Clark shareholders will own about 54% of the combined company, while Kenvue shareholders will hold about 46%. The deal, still subject to shareholder and regulatory approval, is expected to close in the second half of 2026.

Combined Company and Brands

The merged business will generate around $32 billion in annual revenue and bring together ten billion-dollar brands under one roof. Kenvue's products, including Tylenol, Listerine, Band-Aid, Aveeno, and Neutrogena, will join Kimberly-Clark's portfolio of Kleenex, Huggies, Cottonelle, Kotex, and Depend.

Kimberly-Clark said it expects $1.9 billion in cost savings within three years of closing. Both companies said they expect the merger to strengthen their position in health and wellness and household essentials markets.

Market Reaction and Next Steps

Kenvue's stock rose 12% Monday following the announcement, while Kimberly-Clark shares fell nearly 15%. Kenvue's shares have lost about half their value since the company was spun off from Johnson & Johnson in 2023.

Kimberly-Clark Chairman and CEO Mike Hsu will lead the combined company, which will keep its headquarters in Irving, Texas, and maintain operations in Kenvue's locations. Three members of Kenvue's board will also join Kimberly-Clark's board.

Image credit: Andy Dean Photography/Shutterstock

Find Thomasnet Suppliers and Services

Pharmaceuticals

Health Care Products

Personal Care Products